Funapide
![]() | |
Clinical data | |
---|---|
Routes of administration | By mouth, topical |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H14F3NO5 |
Molar mass | 429.351 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.[1][3]
See also[]
- List of investigational analgesics
References[]
- ^ a b c Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
- ^ a b McMahon S, Koltzenburg M, Tracey I, Turk DC (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
- ^ a b Xenon Pharma. "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders".
- ^ a b Xenon Pharma (2012). "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Archived from the original on 2014-07-26. Retrieved 2014-07-20.
External links[]
Categories:
- Drugs not assigned an ATC code
- Analgesics
- Benzodioxoles
- Furans
- Local anesthetics
- Trifluoromethyl compounds
- Sodium channel blockers
- Spiro compounds
- Analgesic stubs